Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Bartsch

Showing results (171-180 of 298) with videos related to

Pageof 30
Sort By:
Life Sciences|February 2, 2016
Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitroJasmina Makarević, Igor Tsaur, Eva Juengel, et al.
The Journal of Urology|November 16, 2007
Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patientsMichael Mitterberger, Rainer Marksteiner, Eva Margreiter, et al.
Urology|February 1, 2003
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trialRoger S Kirby, Claus Roehrborn, Peter Boyle, et al.
Critical Reviews in Oncology/Hematology|November 29, 2005
Cancer of the prostateSergio Bracarda, Ottavio de Cobelli, Carlo Greco, et al.
BJU International|January 25, 2007
Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladderMichael Mitterberger, Leo Pallwein, Johann Gradl, et al.
Plos One|August 20, 2014
Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2Jasmina Makarević, Jochen Rutz, Eva Juengel, et al.
Journal of Cellular and Molecular Medicine|May 1, 2014
Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cellsJasmina Makarević, Nassim Tawanaie, Eva Juengel, et al.
Investigational New Drugs|July 18, 2012
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258Stefan Vallo, Jens Mani, Matthias Stastny, et al.
The International Journal of Biological Markers|July 28, 2009
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centersCarsten Stephan, Chris Bangma, Giulio Vignati, et al.
The Prostate|January 27, 2004
Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening populationHannes Steiner, Patrizia Moser, Martina Hager, et al.
Pageof 30

Showing results (171-180 of 298) with videos related to

Sort By:
Pageof 30
Life Sciences|February 2, 2016
Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitroJasmina Makarević, Igor Tsaur, Eva Juengel, et al.
The Journal of Urology|November 16, 2007
Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patientsMichael Mitterberger, Rainer Marksteiner, Eva Margreiter, et al.
Urology|February 1, 2003
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trialRoger S Kirby, Claus Roehrborn, Peter Boyle, et al.
Critical Reviews in Oncology/Hematology|November 29, 2005
Cancer of the prostateSergio Bracarda, Ottavio de Cobelli, Carlo Greco, et al.
BJU International|January 25, 2007
Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladderMichael Mitterberger, Leo Pallwein, Johann Gradl, et al.
Plos One|August 20, 2014
Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2Jasmina Makarević, Jochen Rutz, Eva Juengel, et al.
Journal of Cellular and Molecular Medicine|May 1, 2014
Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cellsJasmina Makarević, Nassim Tawanaie, Eva Juengel, et al.
Investigational New Drugs|July 18, 2012
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258Stefan Vallo, Jens Mani, Matthias Stastny, et al.
The International Journal of Biological Markers|July 28, 2009
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centersCarsten Stephan, Chris Bangma, Giulio Vignati, et al.
The Prostate|January 27, 2004
Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening populationHannes Steiner, Patrizia Moser, Martina Hager, et al.
Pageof 30